Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

126.34 +0.01 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,409,568
Open 125.88
Bid (Size) 125.01 (100)
Ask (Size) 126.69 (200)
Prev. Close 126.33
Today's Range 124.19 - 127.27
52wk Range 107.75 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗
Via Chartmill
News headline image
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda. 
Via Benzinga

Performance

YTD
+3.9%
+3.9%
1 Month
-3.6%
-3.6%
3 Month
-7.3%
-7.3%
6 Month
+1.1%
+1.1%
1 Year
+14.0%
+14.0%

More News

Read More
News headline image
This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
Via MarketBeat
Topics ETFs
News headline image
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
3 S&P 500 Stocks with Exciting Potential
Via StockStory
Topics Stocks
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
Via Benzinga
News headline image
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
Via StockStory
News headline image
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗
Via Benzinga
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire
News headline image
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
Via MarketBeat
News headline image
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
Via MarketBeat
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 126.34
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/30/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 158.41B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 158B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.